目的：研究就诊于我院新生血管性年龄相关性黄斑变性(NV-AMD)患者使用雷珠单抗治疗后3年的疗效。

方法：回顾性研究。共纳入73例(101眼)患者。根据入组时视力情况(ETDRS chart)，患者被分为3组。第1组：视力≤ 35； 第2组：视力36～54； 第3组：视力≥55字母。患者接受3次，每次0.5 mg的雷珠单抗负荷剂量，之后根据病情决定是否再次注射。对患者每月进行一次随访，进行视力、详细的眼前节及眼底的生物显微镜，以及光学相干断层扫描(OCT)检查。对最接近12、24、36mo的视力检查结果进行分析。

结果：纳入的101眼中，男性57眼，女性44眼。患者平均年龄75.1岁。治疗24mo和36mo时，三组患者之间视力变化情况差异均有统计学意义(P=0.002， 0.0001)。治疗36mo后，第2组视力较入组时显著改善(P=0.001)，第3组患者视力改善不显著。随访12、24、36mo时，第1组视力无明显变化的患者人数最多。所有患者平均注射雷珠单抗7.3次，随访次数23.9次。

结论：入组时视力情况尚可的患者视力改善最明显。视力较差和视力较好的患者视力改变不明显。最终视力与注射次数无明显关系。

METHODS: Retrospective study. Visual acuity(VA), a full biomicroscopic examination(anterior segment and fundus), and optical coherence tomography(OCT)findings were noted at every visit. All patients were followed monthly. The VA values for the visits closest to 12, 24, and 36mo were analysed. Totally 101 eyes of 73 patients were enrolled. According to the initial VA, the patients were divided three groups: initial VA ≤ 35(Group 1), 36-54(Group 2), and ≥55 letters(Group 3). After three loading doses of 0.5 mg Ranibizumab if retreatment was needed, again, 0.5 mg Ranibizumab was administered.

RESULTS: Totally 57 of the 101 eyes were from males and 44 were from females. The average age was 75.1y. The difference on the changes of VA among three groups at 24 and 36mo were statistically significant(P=0.002 and 0.0001 respectively). At the end of the 36-month follow-up the VA increase in Group 2 was significant(P=0.001). At the 12, 24 and 36mo visits most of the eyes showed no VA loss and most of these eyes were in Group 1. The average number of injections administered was 7.3 and the average number of visits was 23.9 during the follow-up.

CONCLUSION: VA improvement was significant in those with mild initial VA(36-54 letters). Most eyes showed no VA loss regardless of the initial VA. No correlation between the final VA and the average number of injections.